NeuClone Reveals Rivals To Opdivo And Keytruda

Australian Biosimilars Specialist Is Developing Nivolumab And Pembrolizumab

 
• By David Wallace
  
Spotlights
Neuclone has revealed two of its biosimilar candidates • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products